SLP0904: Novel class substance group active against soft tissue infections

Target Indication:
Topical soft tissue infections

Stage: Preclinical – Entering Phase I in 2014

Chemistry: First in class small molecule <500MWT

Potency: MIC of <1.0µg/ml against multi-drug resistant Staph. aureus

Antibiotic spectrum:
Gram positive MRSA, MSSA and Mupirocin resistant Staphylococci

Safety: Low toxicity and not able to enter the blood stream through topical application.

Efficacy: Efficacious in-vivo in Guinea Pig skin MRSA model demonstrating

Production: Low production costs (cheap and easy chemistry)

Mode of action: Addresses multiple targets

For more information please email: